HeartFlow Appoints Cybersecurity Expert Julie Cullivan to its Board of Directors

“Julie’s long-time leadership in the technology and cybersecurity industry will provide substantial strategic guidance as HeartFlow continues to scale its business and provide physicians and patients with a world-class, integrated solution for coronary artery disease management,” said William C. Weldon, Chairman of the Board of Directors, HeartFlow. “Julie’s unique depth of knowledge and experience of how to scale technology companies, while maintaining data security and privacy, makes her an ideal addition to HeartFlow’s Board of Directors.”

Ms. Cullivan has more than two decades of operational and technical experience across some of the world’s largest cybersecurity and IT brands. She has spent her career helping enterprise software and cloud companies scale their business and is a sought-after speaker on diversity and inclusion, security as a boardroom imperative, innovation and building high-impact teams. Before Forescout, Ms. Cullivan held executive roles focused on global sales and business operations at FireEye, Autodesk, McAfee, EMC and Oracle.

“HeartFlow is a mission-driven company that applies fascinating artificial intelligence, cloud and security technologies to tackle coronary artery disease, the world’s leading cause of death,” said Julie Cullivan. “I look forward to bringing my software, cloud and operational expertise to the Board so we can shape the future of cardiac care and save lives.”

In addition to HeartFlow, Ms. Cullivan serves on the Board of Directors for Axon Enterprise, Inc, and has a bachelor’s degree in finance from Santa Clara University.

About the HeartFlow FFRct Analysis

The HeartFlow Analysis is a non-invasive, cardiac test for stable symptomatic patients with CAD, the leading cause of death worldwide. Starting with a standard coronary CTA, the HeartFlow Analysis leverages deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries. This information helps physicians evaluate the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRct value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.

Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 400 peer-reviewed publications, including long-term data out to five years. The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test.¹ To date, clinicians around the world have used the HeartFlow Analysis for more than 70,000 patients to aid in the diagnosis of heart disease.

About HeartFlow, Inc.

HeartFlow, Inc. is a leader in revolutionizing precision heartcare, uniquely combining human ingenuity with advanced technology. Our non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. Our technology is reflective of our Silicon Valley roots and incorporates decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe and Japan. For more information, visit www.heartflow.com.

1. Driessen, R., et al. Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis. J Am Coll Cardiol. 2019;73(2),161-73.